I am a
Home I AM A Search Login

Rejected

Share this

Brexanolone: A Novel Drug for the Treatment of Postpartum Depression.

To review the pharmacology, efficacy, and safety of Brexanolone and define its role in the treatment of postpartum depression.

Learn More >

Ibuprofen and postoperative bleeding in children undergoing tonsillectomy or adenotonsillectomy. a systematic review and meta-analysis of randomized clinical trials.

: Ibuprofen is a drug widely used in children who underwent elective tonsillectomy or adenotonsillectomy because compared to the other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) it is considered a safe drug with a low risk of postoperative bleeding.

Learn More >

Clinical and demographic characteristics of children and adolescents with acute vertigo symptoms: A cross-sectional study.

Vertigo is one of the rarely diagnosed disorders during childhood due to insufficient description of their experiencs to the physician. The clinical features of children and adolescents admitted by acute vertigo symptoms were investigated to elaborate retrospectively.

Learn More >

Adverse Events and Complications Associated With Intrathecal Drug Delivery Systems: Insights From the Manufacturer and User Facility Device Experience (MAUDE) Database.

Modern intrathecal drug delivery systems (IDDS) are technologically advanced to deliver medication through various automated and patient-controlled programs. They also are associated with unique complications ranging from post-operative complications, medication-related adverse events (AE), device malfunction, to refill associated AE.

Learn More >

Trends and patterns in the use of opioids among metastatic breast cancer patients.

Opioid use among metastatic breast cancer (MBC) patients has not been well-studied. This study examined the trends and patterns of opioid use among working-age, privately insured patients diagnosed with MBC. Using MarketScan data, we identified female patients diagnosed with MBC in 2006-2015. We determined the proportion of patients who filled a prescription for an opioid and calculated days' supply and daily morphine milligram equivalents (MMEs) from 1 year prior to diagnosis till 1 year after. We assessed the trend in opioid use over the 10-year study period and examined opioid usage patterns after the diagnosis of MBC. Among 24,752 patients included, 11,579 (46.8%) had an opioid prescription within 1 year before diagnosis of MBC, and 20,416 (81.4%) had an opioid prescription within 1 year after diagnosis. The proportion of patients with opioid prescriptions after diagnosis was relatively stable from 2006 to 2015. However, both the median daily MME and median days' supply decreased over time with most of the decline from the subgroup of patients with prior prescription opioid use. Most patients received an opioid prescription in the first month after diagnosis (57.3%), dropping to approximately 20% from 3 to 12 months after diagnosis. Also, the median days' supply increased substantially during the year after diagnosis for patients who received opioids (from 7 to 19). Most women with MBC require opioid analgesia within the first month after diagnosis. Judicious, long-term management of pain after diagnosis of MBC will continue to be necessary for many patients.

Learn More >

Internal neurolysis: ‘nerve combing’ for trigeminal neuralgia without neurovascular conflict – early UK outcomes.

Internal neurolysis (INL) is a surgical procedure where trigeminal nerve fibres are separated between the pons and to relieve trigeminal neuralgia (TN). We report pain and functional outcomes to evaluate its safety and efficacy.

Learn More >

Protease-activated receptor 1 as a potential therapeutic target for COVID-19.

Acute respiratory disease caused by a novel coronavirus (SARS-CoV-2) has spread all over the world, since its discovery in 2019, Wuhan, China. This disease is called COVID-19 and already killed over 1 million people worldwide. The clinical symptoms include fever, dry cough, dyspnea, headache, dizziness, generalized weakness, vomiting, and diarrhea. Unfortunately, so far, there is no validated vaccine, and its management consists mainly of supportive care. Venous thrombosis and pulmonary embolism are highly prevalent in patients suffering from severe COVID-19. In fact, a prothrombotic state seems to be present in most fatal cases of the disease. SARS-CoV-2 leads to the production of proinflammatory cytokines, causing immune-mediated tissue damage, disruption of the endothelial barrier, and uncontrolled thrombogenesis. Thrombin is the key regulator of coagulation and fibrin formation. In severe COVID-19, a dysfunctional of physiological anticoagulant mechanisms leads to a progressive increase of thrombin activity, which is associated with acute respiratory distress syndrome development and a poor prognosis. Protease-activated receptor type 1 (PAR1) is the main thrombin receptor and may represent an essential link between coagulation and inflammation in the pathophysiology of COVID-19. In this review, we discuss the potential role of PAR1 inhibition and regulation in COVID-19 treatment.

Learn More >

An Examination of Chronic Pain Indices and the Updated Posttraumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental-Disorders-Fifth Edition.

Chronic pain and post-traumatic stress disorder (PTSD) comorbidity is prevalent among veterans and is associated with increased levels of pain severity and pain-related disability. An improved understanding of the relationship between these co-occurring disorders, in addition to effective integrated treatments, will develop by considering the changes to the PTSD diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). The current study examined the relationship between the revised PTSD Checklist for DSM-5 (PCL-5) symptom clusters (i.e., intrusion, avoidance, negative alterations in cognition and mood [NACM], and arousal) and chronic pain measurements (i.e., pain severity, interference, and disability).

Learn More >

Imaging the distribution of DMPBD and terpinen-4-ol inclusion complexes with 2-hydroxypropyl-β-cyclodextrin by using TOF-SIMS.

The distribution of terpinen-4-ol (TP4ol) and DMPBD inclusion complexes with 2-hydroxypropyl-β-cyclodextrin (HPbCD) in human skin has been investigated using the TOF-SIMS technique. TP4ol and DMPBD have been found to be major components of Zingiber cassumunar Roxb. (Plai) oil extracted by steam distillation. The results mainly show accumulation of TP4ol and DMPBD inclusion complexes with HPbCD in the epidermis and dermis whereas these two compounds without cyclodextrin cannot penetrate into the epidermis. This approach can be expanded for investigation of anti-inflammatory action and relief of muscle pain.

Learn More >

Chronic cancer and non cancer pain and opioid-induced hyperalgesia share common mechanisms: neuroinflammation and central sensitization.

Neuroinflammation, a peculiar form of inflammation that occurs in response to noxious stimuli in peripheral and central nervous system (CNS), consists in altered vascular permeability followed by leukocyte recruitment and activation in the inflamed tissue, release of inflammatory mediators including cytokines and chemokines, and finally in activation of microglia and astrocytes in the spinal cord and CNS. This phenomenon mediates and even worsen the inflammatory pain in many painful states and is responsible for central sensitization leading to pain chronicity. We describe the major neuroinflammatory mechanisms shared by cancer and non cancer pain. Particular attention is given to two different chronic inflammatory painful diseases such as the Complex Regional Pain Syndrome and the Rheumatoid Arthritis as prototypes of neuroinflammatory diseases (gliopathies). In addition, we describe the complexity of tumor microenvironment, their main cellular components (tumor cells, tumor infiltrating leukocytes and sensory neurons) and their reciprocal interactions that characterize different forms and intensity of cancer pain. We also hypothesize that one type of cancer pain, the breakthrough pain, can be attributable to receptor-mediated interaction of opioids with tumor cells and intratumoral leukocytes. Surprisingly, long-term opioid treatment shares the same neuroinflammatory potential responsible for the chronicity of both cancer and non cancer pain, thus resulting in paradoxical worsening rather than relieving pain. This paradox has up-set the world of pain therapy, with neuroinflammation now being a main target of emerging therapies.

Learn More >

Search